Literature DB >> 17276172

A public health approach to cervical cancer control: considerations of screening and vaccination strategies.

Sue Goldie1.   

Abstract

Cervical cancer remains a leading cause of cancer death among women living in low-resource settings. In the last 3 decades, cytologic screening has -in theory -been available and yet more than 6 million women have died of this preventable disease. The necessary resources, infrastructure, and technological expertise, together with the need for repeated screenings at regular intervals, make cytologic screening difficult to implement in poor countries. As noncytologic approaches for the detection of HPV, simple visual screening methods for anogenital lesions caused by HPV, and the availability of an HPV-16/18 vaccine will enhance the linkage between screening and treatment, multiple factors will need to be considered when designing new, or modifying existing prevention strategies. Countryspecific decisions regarding the best strategy for cervical cancer control will need to rely on data from many sources and take into account complex epidemiologic, economic, social, political, and cultural factors, and be made despite uncertainty and incomplete information. A rigorous decision analytic approach using computerbased modeling methods enables linkage of the knowledge gained from empirical studies to real-world situations. This chapter provides an introduction to these methods, reviews lessons learned from cost-effectiveness analyses of cervical cancer screening in developed and developing countries, and emphasizes important qualitative themes to consider in designing cervical cancer prevention policies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17276172     DOI: 10.1016/S0020-7292(07)60016-2

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  5 in total

1.  Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers.

Authors:  J T-C Chang; T-F Kuo; Y-J Chen; C-C Chiu; Y-C Lu; H-F Li; C-R Shen; A-J Cheng
Journal:  Cancer Gene Ther       Date:  2010-10-01       Impact factor: 5.987

Review 2.  A health services research agenda for cellular, molecular and genomic technologies in cancer care.

Authors:  Louise Wideroff; Kathryn A Phillips; Gurvaneet Randhawa; Anita Ambs; Katrina Armstrong; Charles L Bennett; Martin L Brown; Molla S Donaldson; Michele Follen; Sue J Goldie; Robert A Hiatt; Muin J Khoury; Graham Lewis; Howard L McLeod; Margaret Piper; Isaac Powell; Deborah Schrag; Kevin A Schulman; Joan Scott
Journal:  Public Health Genomics       Date:  2009-02-20       Impact factor: 2.000

3.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Joshua A Salomon; Karen M Kuntz; Sue J Goldie
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

4.  Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies.

Authors:  Taweewun Hunsawong; Sineewanlaya Wichit; Thipwipha Phonpakobsin; Yongyuth Poolpanichupatam; Chonticha Klungthong; Napaporn Latthiwongsakorn; Butsaya Thaisomboonsuk; Rawiwan Im-Erbsin; In-Kyu Yoon; Damon W Ellison; Louis R Macareo; Anon Srikiatkhachorn; Robert V Gibbons; Stefan Fernandez
Journal:  Heliyon       Date:  2017-03-21

5.  Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases.

Authors:  Luciano Mariani; Sonia Pagliusi
Journal:  J Exp Clin Cancer Res       Date:  2008-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.